Kymera Investor Day Presentation Deck slide image

Kymera Investor Day Presentation Deck

KT-474 Demonstrates Broadest Anti-inflammatory Effect Compared to Other Clinical Agents Agent/Stimulus Target IFNY IRAK4 (degrader) ✓ ✓ KT-474/LPS KT-474/R848 CA-4948/R848 GS-5718/R848 ATI-450/LPS ATI-450/IL-13 LY2775240/LPS Iberdomide/LPS JNJ-61803534/ T cell activation Inhibition of Ex Vivo Disease Relevant Cytokine/Chemokine Stimulation by Anti-Inflammatory Agents in Ph1 Studies TNFa IL-1B IL-6 IL-8 IL-17 ✓ ✓ * Non-selective IRAK4 (degrader) IRAK4* (inhibitor) IRAK4 (inhibitor) MK2 MK2 PDE4 Ikaros/ Aiolos RORY ✓ ✓ KYMERA ©2021 KYMERA THERAPEUTICS, INC. ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ ✓ IL-12 ✓ ✓ IL-23 ✓ IL-10 ✓ Iberdomide: Schafer PH, et al. Ann Rheum Dis 2018;77:1516-1523; LY2775240: Patel DR, et al. Clin Transl Sci. 2021;14:1037-1048; JNJ61803534: Xue X, et al. Sci Rep 2021;11:11066- 80; MK2: Aclaris 2021 Company Overview; CA-4948: Booher RN, et al. ASH Annual Meeting 2018, Poster #4168; GS-5718: Roedder S, et al. ACR Convergence 2021, Poster #0185 KYMERA R&D DAY - December 16th, 2021 PAGE 31
View entire presentation